title: Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome.
abstract: OBJECTIVE
  To compare glycaemic control and pregnancy outcome in women with type 1 diabetes treated with the long-acting insulin analogues detemir or glargine.
  
  
  METHODS
  Retrospective study of singleton pregnancies from 2007 to 2011 in women with type 1 diabetes with a single living fetus at 22 weeks using either insulin detemir (n = 67) or glargine (n = 46) from conception.
  
  
  RESULTS
  Baseline characteristics were similar in the detemir and glargine groups. Haemoglobin A1c was comparable at 8 weeks (median 6.6% (range 5.6-9.8) vs. 6.8% (5.4-10.1), p = 0.15) and at 33 weeks (6.1% (5.1-7.6) vs. 6.2% (4.8-7.2), p = 0.38). The incidence of severe hypoglycaemia was comparable (15 (23%) vs. 10 (23%), p = 0.98). Pre-eclampsia occurred in 9 (14%) vs. 8 (18%), p = 0.52, pre-term delivery in 21 (31%) vs. 16 (35%), (p = 0.70) and 33 (49%) vs. 14 (30%) infants were large for gestational age (p = 0.046). No perinatal deaths were observed. One offspring in each group was born with a major congenital malformation.
  
  
  CONCLUSIONS
  Glycaemic control and pregnancy outcome were comparable in women using insulin detemir or glargine, except for a lower prevalence of large for gestational age infants in women on glargine. The use of both long-acting insulin analogues during pregnancy seems safe.
authors.affiliation: Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark. nicolinecallesen@hotmail.com
authors.forename: Nicoline F
authors.initials: NF
authors.lastname: Callesen
authors.forename: Julie
authors.initials: J
authors.lastname: Damm
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Mathiesen
authors.forename: Lene
authors.initials: L
authors.lastname: Ringholm
authors.forename: Peter
authors.initials: P
authors.lastname: Damm
authors.forename: Elisabeth R
authors.initials: ER
authors.lastname: Mathiesen
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000494:pharmacology / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011254:Pregnancy in Diabetics / Q000188:drug therapy*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D000069057:Insulin Detemir